After the return of value was lower than expected, the performance of Dong-E-E-Jiao Co.Ltd(000423) ( Dong-E-E-Jiao Co.Ltd(000423) , SZ), which made strategic adjustment, recovered significantly last year.
On March 25, Dong-E-E-Jiao Co.Ltd(000423) announced the financial report of 2021. Data show that last year, the company achieved an operating revenue of 3.849 billion yuan, a year-on-year increase of 12.89%; The net profit attributable to the shareholders of the listed company was 440 million yuan, a year-on-year increase of 917.43%
Dong-E-E-Jiao Co.Ltd(000423) disclosed data show that among the main revenue components, the sales of main products rebounded in 2021, and the pharmaceutical business increased by 510 million yuan year-on-year; Taohuaji’s growth led to a year-on-year increase of 56 million yuan in the revenue of health products of its subsidiary; Affected by the contraction of the scale of breeding trading business, the income of the breeding sector decreased by 118 million yuan year-on-year.
As for the reasons for the change, Dong-E-E-Jiao Co.Ltd(000423) in the performance forecast, the company insists on taking consumers as the center, focusing on customer growth and retention, accelerating product innovation, strengthening the transformation of scientific research achievements, constantly releasing brand productivity and realizing stable and benign growth.
In 2021, Dong-E-E-Jiao Co.Ltd(000423) has walked out of the shadow of the performance explosion in 2019. In 2019, Dong-E-E-Jiao Co.Ltd(000423) lost 455 million yuan because the value return strategy was lower than expected.
Since then, in order to reverse the performance loss, Dong-E-E-Jiao Co.Ltd(000423) started digital transformation and launched online sales channels.
